Patents Assigned to Gilead Calistoga LLC
-
Patent number: 10730879Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.Type: GrantFiled: September 6, 2016Date of Patent: August 4, 2020Assignee: Gilead Calistoga LLCInventors: Ernest Carra, Michael Gerber, Bing Shi, Keiko Sujino, Duong Tran, Fang Wang, Jerry B. Evarts
-
Patent number: 10442805Abstract: Polymorphs of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed. Solvent forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are also disclosed.Type: GrantFiled: June 16, 2017Date of Patent: October 15, 2019Assignee: Gilead Calistoga LLCInventors: Suzanne Buttar, Ernest Carra, Tracy Ehiwe, Duong Tran, Fang Wang, Christopher Worrall, Jerry Evarts
-
Patent number: 10154998Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.Type: GrantFiled: September 27, 2016Date of Patent: December 18, 2018Assignee: Gilead Calistoga LLCInventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
-
Patent number: 10059677Abstract: A process for the synthesis of benzoxazinone containing compounds which may be useful precursors for synthesizing compounds for the treatment of cancer, is hereby disclosed.Type: GrantFiled: December 28, 2016Date of Patent: August 28, 2018Assignee: Gilead Calistoga LLCInventors: Stacy Bremner, Jerry Evarts, Keiko Sujino, Duong Tran, Dragos Vizitiu
-
Patent number: 10047060Abstract: A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.Type: GrantFiled: November 17, 2017Date of Patent: August 14, 2018Assignee: Gilead Calistoga LLCInventors: Stacy Bremner, Jerry Evarts, Keiko Sujino, Duong Tran, Dragos Vizitiu
-
Patent number: 9708327Abstract: Polymorphs of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed. Solvent forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are also disclosed.Type: GrantFiled: December 18, 2014Date of Patent: July 18, 2017Assignee: GILEAD CALISTOGA LLCInventors: Suzanne Buttar, Ernest Carra, Tracy Ehiwe, Duong Tran, Fang Wang, Christopher Worrall, Jerry Evarts
-
Patent number: 9492449Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.Type: GrantFiled: March 9, 2012Date of Patent: November 15, 2016Assignee: Gilead Calistoga LLCInventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese, Brian Lannutti, Langdon Miller, Thomas M. Jahn
-
Patent number: 9469643Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.Type: GrantFiled: September 22, 2014Date of Patent: October 18, 2016Assignee: Gilead Calistoga, LLC.Inventors: Ernest Carra, Michael Gerber, Bing Shi, Keiko Sujino, Duong Tran, Fang Wang, Jerry B. Evarts
-
Patent number: 9266878Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: GrantFiled: April 14, 2015Date of Patent: February 23, 2016Assignee: Gilead Calistoga LLCInventors: Jerry Evarts, Leena Patel, Jennifer A. Treiberg, Stephane Perreault, Arthur Yeung, Lafe J. Purvis, II, Musong Kim
-
Patent number: 9238070Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.Type: GrantFiled: February 7, 2013Date of Patent: January 19, 2016Assignee: Gilead Calistoga LLCInventors: W. Michael Gallatin, Roger G. Ulrich, Neill A. Giese
-
Publication number: 20150218154Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: ApplicationFiled: April 14, 2015Publication date: August 6, 2015Applicant: Gilead Calistoga LLCInventors: Jerry Evarts, Leena Patel, Jennifer A. Treiberg, Stephane Perreault, Arthur Yeung, Lafe J. Purvis, II, Musong Kim
-
Patent number: 9029384Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which n, m, R1, R2, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: GrantFiled: December 20, 2013Date of Patent: May 12, 2015Assignee: Gilead Calistoga, LLC.Inventors: Jerry Evarts, Leena Patel, Joshua Kaplan, Jennifer A. Treiberg, Stephane Perreault, Gary Phillips
-
Patent number: 9018221Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: GrantFiled: December 20, 2013Date of Patent: April 28, 2015Assignee: Gilead Calistoga, LLCInventors: Jerry Evarts, Leena Patel, Jennifer A. Treiberg, Stephane Perreault, Arthur Yeung, Lafe J. Purvis, II, Musong Kim
-
Publication number: 20150080572Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.Type: ApplicationFiled: September 22, 2014Publication date: March 19, 2015Applicant: GILEAD CALISTOGA LLCInventors: Ernest CARRA, Michael GERBER, Bing SHI, Keiko SUJINO, Duong TRAN, Fang WANG, Jerry B. EVARTS
-
Patent number: 8865730Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.Type: GrantFiled: March 5, 2013Date of Patent: October 21, 2014Assignee: Gilead Calistoga LLCInventors: Ernest Carra, Michael Gerber, Bing Shi, Keiko Sujino, Duong Tran, Fang Wang, Jerry B. Evarts
-
Publication number: 20140179718Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which n, m, R1, R2, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: ApplicationFiled: December 20, 2013Publication date: June 26, 2014Applicant: GILEAD CALISTOGA LLCInventors: Jerry EVARTS, Leena PATEL, Joshua KAPLAN, Jennifer A. TREIBERG, Stephane PERRAULT, Gary PHILLIPS
-
Publication number: 20140179673Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: ApplicationFiled: December 20, 2013Publication date: June 26, 2014Applicant: GILEAD CALISTOGA LLCInventors: Jerry EVARTS, Leena PATEL, Jennifer A. TREIBERG, Stephane PERREAULT, Arthur YEUNG, Lafe J. PURVIS, II, Musong KIM
-
Patent number: 8691829Abstract: The invention provides methods to treat certain liver disorders by administering a compound that inhibits PD K isoforms, particularly the delta isoform. It further provides specific compounds useful for these methods and ways to identify subjects who are particularly suitable for receiving these treatments.Type: GrantFiled: July 21, 2010Date of Patent: April 8, 2014Assignee: Gilead Calistoga LLCInventor: Roger G. Ulrich
-
Publication number: 20140066386Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.Type: ApplicationFiled: February 7, 2013Publication date: March 6, 2014Applicant: GILEAD CALISTOGA LLCInventor: Gilead Calistoga LLC
-
Publication number: 20140051696Abstract: Provided herein are methods that relate to a novel therapeutic strategy for treatment of cancer, including hematological malignancies such as leukemia, lymphoma, and multiple myeloma. In particular, the method includes administration of a PI3K? inhibitor and a Syk inhibitor.Type: ApplicationFiled: August 14, 2013Publication date: February 20, 2014Applicant: GILEAD CALISTOGA LLCInventors: Brian J. LANNUTTI, Julie DI PAOLO, Heather WEBB, Adam KASHISHIAN